Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

Summary

The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progression-free survival after adjusting for potential confounder variables such as age, performance status and comorbidity burden.

Conditions

• HNSCC
• Oral Cavity Cancer
• Oropharynx Cancer
• Hypopharynx Cancer
• Larynx Cancer

Sponsors & Collaborators

• Charite University, Berlin, Germany

  collaborator OTHER

• Johann Wolfgang Goethe University Hospital

  collaborator OTHER

• University Hospital, Zürich

  collaborator OTHER

• Wuerzburg University Hospital

  collaborator OTHER

• University Hospital Schleswig-Holstein

  collaborator OTHER

• Johannes Gutenberg University Mainz

  collaborator OTHER

• University Hospital Munich

  collaborator OTHER

• Friedrich-Alexander-Universität Erlangen-Nürnberg

  collaborator OTHER

• Case Western Reserve University

  collaborator OTHER

• Icahn School of Medicine at Mount Sinai

  collaborator OTHER

• Ohio State University

  collaborator OTHER

• German Oncology Center, Cyprus

  collaborator OTHER

• University of Leipzig

  collaborator OTHER

• Johns Hopkins University

  collaborator OTHER

• Martin-Luther-Universität Halle-Wittenberg

  collaborator OTHER

• University of Giessen

  collaborator OTHER

• Brno University Hospital

  collaborator OTHER

• Jena University Hospital

  collaborator OTHER

• University Hospital Freiburg

  lead OTHER

Principal Investigators

• Nils H. Nicolay, MD, PhD · Department of Radiation Oncology, Medical Center - University of Freiburg

• Alexander Rühle, MD · Department of Radiation Oncology, Medical Center - University of Freiburg

Eligibility

Min Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-06-01

Primary Completion

2026-12-31

Completion

2026-12-31

Countries

• United States
• Cyprus
• Czechia
• Germany
• Switzerland

Study Locations